<DOC>
	<DOCNO>NCT01238146</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose obatoclax mesylate give together rituximab bendamustine hydrochloride see well work compare rituximab bendamustine hydrochloride alone treat patient relapsed refractory non-Hodgkin lymphoma . Obatoclax mesylate may stop growth cancer cell block protein need cell growth . Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell help kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Drugs use chemotherapy , bendamustine hydrochloride , also work different way stop growth cancer cell , either kill cell stop divide . Giving obatoclax mesylate together rituximab bendamustine hydrochloride may kill cancer cell</brief_summary>
	<brief_title>Obatoclax Mesylate , Rituximab , Bendamustine Hydrochloride Treating Patients With Relapsed Refractory Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine dose-limiting toxicity ( DLT ) maximum-tolerated dose ( MTD ) combination obatoclax mesylate , rituximab , bendamustine hydrochloride patient relapse refractory , indolent , B-cell non-Hodgkin lymphoma ( phase I ) . II . To define qualitative quantitative toxicity combination obatoclax mesylate , rituximab , bendamustine ( phase I ) . III . To detect improvement median progression-free survival ( PFS ) 6 12 month addition obatoclax mesylate rituximab bendamustine hydrochloride patient indolent B-cell non-Hodgkin lymphoma ( phase II ) . SECONDARY OBJECTIVES : I . To determine overall objective response rate combination obatoclax mesylate , rituximab , bendamustine versus rituximab bendamustine hydrochloride patient relapse refractory , indolent , B-cell non-Hodgkin lymphoma . II . To characterize two-year PFS patient indolent B-cell non-Hodgkin lymphoma receive obatoclax mesylate , rituximab , bendamustine hydrochloride versus rituximab bendamustine hydrochloride . III . To assess pharmacokinetics obatoclax mesylate patient relapse refractory , indolent , B-cell non-Hodgkin lymphoma . IV . To assess pharmacokinetics combination bendamustine hydrochloride obatoclax mesylate patient relapse refractory , indolent , B-cell non-Hodgkin lymphoma . V. To determine effect combination rituximab , bendamustine hydrochloride , obatoclax mesylate histone-oligodeoxynucleotide ( ODNA ) level activate Bax Bak pro-apoptotic protein peripheral blood mononuclear cell bone marrow aspirate specimen . VI . To identify association genetic polymorphism drug-metabolizing enzyme , transporter , target gene pharmacokinetics , pharmacodynamics , clinical outcome . OUTLINE : This phase I , dose-escalation study obatoclax mesylate follow randomized phase II study . PHASE I : Patients receive obatoclax mesylate IV 3 hour day 1-3 , rituximab IV 4-8 hour day 1 ( day 3 course 1 ) , bendamustine hydrochloride IV 30 minute day 1-2 ( day 2-3 course 1 ) . Treatment repeat every 28 day maximum 6 course absence disease progression unacceptable toxicity . PHASE II : Patients stratify accord prior bendamustine hydrochloride ( yes v ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive obatoclax mesylate IV 3 hour day 1-3 , rituximab IV 4-8 hour day 1 , bendamustine hydrochloride IV 30 minute day 1-2 . ARM II : Patients receive rituximab bendamustine hydrochloride arm I . In arm , treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients undergo blood bone marrow sample collection baseline periodically study pharmacokinetics , pharmacodynamic , pharmacogenetic study . After completion study therapy , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm indolent Bcell nonHodgkin lymphoma ( NHL ) , include follow subtypes recognize WHO classification : Marginal zone lymphoma Lymphoplasmacytic lymphoma Follicular lymphoma Mantle cell lymphoma Transformed lymphoma lowgrade , indolent NHL allow provided patient receive ≥ 1 prior therapy indolent disease Must receive ≥ 1 prior therapy Relapsed disease autologous allogeneic stem cell transplantation ( SCT ) allow ( phase I ) No relapse allogeneic SCT ( phase II ) No know CNS lymphoma ECOG performance status 02 ANC ≥ 1,000/µL Platelet count ≥ 50,000/µL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 50 mL/min Not pregnant nursing Fertile patient must use effective contraception prior duration study participation No active hepatitis B infection Patients history hepatitis B ( surface antigen core antibody positive ) must take lamivudine equivalent study therapy No history document human antiglobulin antibody , history allergic reaction attribute compound similar chemical biologic composition rituximab , bendamustine hydrochloride , obatoclax mesylate No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness and/or social situation would limit compliance study requirement HIV infection allow provided patient meet follow criterion : No evidence coinfection hepatitis B C CD4 cell count ≥ 400/mm³ No evidence resistant strain HIV HIV viral load ≤ 10,000 copy HIV RNA/mL patient antiHIV combination antiretroviral therapy OR HIV viral load ≤ 50,000 copy HIV RNA/mL patient antiHIV therapy No history AIDSdefining condition No active secondary malignancy except nonmelanomatous skin cancer No concurrent investigational agent Prior bendamustine hydrochloride allow provided patient complete bendamustinecontaining regimen within past 6 month achieve partial response well More 4 week since prior chemotherapy radiotherapy ( 6 week nitrosoureas mitomycin C ) recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>